Treatment with sacituzumab govitecan was shown to improve the survival of patients with metastatic triple-negative breast cancer compared with physicians’ choice of chemotherapy [184]; a similar survival benefit was observed for patients with metastatic HR-positive/HER2-negative breast cancer, regardless of the Trop-2 expression level [185]. This evidence concerns the gene ERBB2 and breast carcinoma.